Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Inclusion Criteria for Part I:~  * Must have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS).~ * Must have a baseline Expanded Disability Status Scale (EDSS) score between 0.0 and 5.0, inclusive.~Key Inclusion Criteria for Part II:~• Subjects who participated in and completed Part I per protocol.~Key Exclusion Criteria:~* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease.~* Pregnant or nursing women.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Part I Placebo (Type: PLACEBO_COMPARATOR): Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID.
- Part I BG00012 (Type: EXPERIMENTAL): BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
- Part II BG00012 (Type: EXPERIMENTAL): Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).